Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders

a technology analogue, which is applied in the field of adenosine a2a receptor antagonists for the treatment of extrapyramidal syndrome and other movement disorders, can solve the problems of patients with irresistible and unpleasant desire to move their legs, disturbed sleep, and often under-diagnosed common syndrome, so as to prevent eps from occurring

Inactive Publication Date: 2009-01-29
SCHERING CORP
View PDF6 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0018]FIG. 1B represents the mean delay in onset of EPS for each treatment group compared to a vehicle control group.

Problems solved by technology

Often mistaken for agitation or anxiety, this common syndrome is frequently under-diagnosed and is the least responsive to treatment.
RLS is a common disorder that causes patients to have an irresistible and unpleasant desire to move their legs; it usually manifests during periods of inactivity and / or at night, and can disturb sleep.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
  • Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
  • Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders

Examples

Experimental program
Comparison scheme
Effect test

example

[0213]A colony of seven Cebus apella monkeys that were previously sensitized to the chronic effects of haloperidol, exhibit EPS when administered haloperidol acutely (0.3 mg / kg, p.o.). Compound A was administered orally (p.o.) at doses of 0.3-30 mg / kg, in conjunction with haloperidol. The studies were conducted using a within-subjects design such that each monkey received all 6 treatments (vehicle and 5 doses of Compound A) in a crossover, balanced design. In all the studies, the group of seven monkeys exhibited baseline levels of EPS when dosed with haloperidol.

[0214]Compound A produced a dose-dependent reduction in the maximum EPS score (FIG. 1A), as well as a dose-dependent delay in the onset of EPS (FIG. 1B). At a dose of 1 mg / kg, Compound A prevented the onset of EPS in one monkey, and delayed the onset of EPS by 1 hr. Compound A, at a dose of 3 mg / kg, prevented the onset of EPS in two monkeys, and delayed the onset of EPS by almost 2 hr in the remaining monkeys. At 10 and 30 m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
volumeaaaaaaaaaa
angleaaaaaaaaaa
timeaaaaaaaaaa
Login to view more

Abstract

There is disclosed a method for the treatment or prevention of Extra Pyramidal syndrome (EPS), dystonia, restless leg syndrome (RLS) or periodic leg movement in sleep (PLMS) comprising the administration of an adenosine A2a receptor antagonist, alone or in combination with other agents useful for treating EPS, dystonia, RLS or PLMS.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Provisional Application 60 / 435,321, filed Dec. 19, 2002.FIELD OF THE INVENTION[0002]The present invention relates to the use of adenosine A2a receptor antagonists for the treatment of a variety of neurological syndromes involving the extra-pyramidal motor system (i.e. Extra-Pyramidal Syndrome) that occur following the acute and chronic use of almost all antipsychotic drugs. The invention also relates to the use of adenosine A2a receptor antagonists for the treatment of other abnormal movement disorders such as restless leg syndrome (RLS) and periodic limb movement in sleep (PLMS).BACKGROUND OF THE INVENTION[0003]Extra-Pyramidal Syndrome (EPS) is a collective term for a series of adverse neurological reactions associated with the use of antipsychotic drugs. There are six different categories of EPS-related neurological syndromes of which four, dystonia, akathisia, pseudoparkinsonism (parkinsonian...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/519A61K31/553A61K31/5415A61K31/554A61K31/551A61K31/55A61P25/00A61K31/195A61K31/198A61K31/4166A61K31/4515A61K31/46A61K31/485A61K31/496A61K31/4985A61K45/06
CPCA61K31/195A61K31/198A61K45/06A61K31/5513A61K31/551A61K31/5415A61K31/4166A61K31/4515A61K31/46A61K31/485A61K31/496A61K31/4985A61K31/519A61K2300/00A61P21/00A61P25/00A61P25/08A61P25/14A61P25/16A61P25/18A61P43/00
Inventor GRZELAK, MICHAELHUNTER, JOHNPOND, ANNAMARIEVAITY, GEOFFREY
Owner SCHERING CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap